metformin has been researched along with Carcinoma, Anaplastic in 32 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This is a randomized controlled trial to test the effect of different doses of metformin in patients with breast cancer and without diabetes, with the aim of modifying the hormonal and metabolic parameters linked to breast cancer prognosis." | 9.16 | Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study. ( Abbà, C; Ambroggio, S; Berrino, F; Biglia, N; Brucato, T; Campagnoli, C; Colombero, R; Danese, S; Donadio, M; Pasanisi, P; Venturelli, E; Zito, G, 2012) |
| "Although a number of in vitro studies have demonstrated the antiproliferative, anti-invasive, and antimetastatic effects of metformin in multiple cancer cell types, its cellular and molecular mechanisms of anti-cancer action in the endometrium of women with polycystic ovary syndrome (PCOS) have not yet been fully elucidated." | 8.90 | Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma. ( Billig, H; Feng, Y; Li, X; Lin, JF; Shao, R, 2014) |
| "The combination of Carboplatin with Paclitaxel is the mainstay treatment for high-grade serous carcinoma; however, many patients with advanced disease undergo relapse due to chemoresistance." | 8.12 | The Antineoplastic Effect of Carboplatin Is Potentiated by Combination with Pitavastatin or Metformin in a Chemoresistant High-Grade Serous Carcinoma Cell Line. ( Duarte, D; Nunes, M; Ricardo, S; Vale, N, 2022) |
| "As metformin can inhibit endometrial carcinoma (EC) cell growth and the insulin growth factor (IGF) system is active in EC, the question of whether t can regulate endometrial carcinoma cell secretion of IGF-1 or expression of IGF-1 receptor (IGF-1R) is of interest." | 7.81 | Metformin down-regulates endometrial carcinoma cell secretion of IGF-1 and expression of IGF-1R. ( Li, MX; Li, XM; Wang, H; Zeng, Z; Zhang, Y, 2015) |
| "We investigated the effect of metformin on growth of differentiated human thyroid cells, anaplastic thyroid carcinoma cells, a doxorubicin-resistant thyroid carcinoma cell line, and thyroid cancer stem cells." | 7.78 | Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. ( Chen, G; Derwahl, M; Renko, K; Xu, S, 2012) |
| "Metformin could inhibit the expression of CCNE1, which is associated with the anti-proliferative effect of tumor cells." | 5.91 | CCNE1 is a potential target of Metformin for tumor suppression of ovarian high-grade serous carcinoma. ( Chu, TY; Huang, HS; Liou, YL; Mei, J; Tian, H; Wang, J; Wu, N; Zhang, W, 2023) |
| "Metformin therapy was prescribed in 190 (81%) patients." | 5.46 | Metformin use associated with lower risk of cancer in patients with diabetes mellitus type 2. ( Gušić, E; Kulo Ćesić, A; Kusturica, J; Maleškić, S; Rakanović-Todić, M; Šečić, D, 2017) |
| "Metformin has been shown to be useful in reducing insulin resistance by restoring sensitivity." | 5.40 | Cisplatin combined with metformin inhibits migration and invasion of human nasopharyngeal carcinoma cells by regulating E-cadherin and MMP-9. ( Jiang, CC; Jiang, ZW; Li, HH; Liu, H; Sun, XJ; Zhang, P, 2014) |
| "A panel of 15 HNSCC cell lines was assayed for glucose and glutamine dependence and sensitivity to metabolic inhibitors." | 5.37 | Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. ( Davis-Malesevich, M; Fokt, I; Frederick, MJ; Myers, JN; Ow, TJ; Pickering, CR; Priebe, W; Sandulache, VC; Zhou, G, 2011) |
| "This is a randomized controlled trial to test the effect of different doses of metformin in patients with breast cancer and without diabetes, with the aim of modifying the hormonal and metabolic parameters linked to breast cancer prognosis." | 5.16 | Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study. ( Abbà, C; Ambroggio, S; Berrino, F; Biglia, N; Brucato, T; Campagnoli, C; Colombero, R; Danese, S; Donadio, M; Pasanisi, P; Venturelli, E; Zito, G, 2012) |
| "Although a number of in vitro studies have demonstrated the antiproliferative, anti-invasive, and antimetastatic effects of metformin in multiple cancer cell types, its cellular and molecular mechanisms of anti-cancer action in the endometrium of women with polycystic ovary syndrome (PCOS) have not yet been fully elucidated." | 4.90 | Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma. ( Billig, H; Feng, Y; Li, X; Lin, JF; Shao, R, 2014) |
| "The combination of Carboplatin with Paclitaxel is the mainstay treatment for high-grade serous carcinoma; however, many patients with advanced disease undergo relapse due to chemoresistance." | 4.12 | The Antineoplastic Effect of Carboplatin Is Potentiated by Combination with Pitavastatin or Metformin in a Chemoresistant High-Grade Serous Carcinoma Cell Line. ( Duarte, D; Nunes, M; Ricardo, S; Vale, N, 2022) |
| "As metformin can inhibit endometrial carcinoma (EC) cell growth and the insulin growth factor (IGF) system is active in EC, the question of whether t can regulate endometrial carcinoma cell secretion of IGF-1 or expression of IGF-1 receptor (IGF-1R) is of interest." | 3.81 | Metformin down-regulates endometrial carcinoma cell secretion of IGF-1 and expression of IGF-1R. ( Li, MX; Li, XM; Wang, H; Zeng, Z; Zhang, Y, 2015) |
| "Sorafenib, a multikinase inhibitor has recently been approved for the treatment of radio-iodine refractory thyroid carcinoma." | 3.81 | Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells. ( Chen, G; Derwahl, M; Nicula, D; Renko, K, 2015) |
| "We investigated the effect of metformin on growth of differentiated human thyroid cells, anaplastic thyroid carcinoma cells, a doxorubicin-resistant thyroid carcinoma cell line, and thyroid cancer stem cells." | 3.78 | Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. ( Chen, G; Derwahl, M; Renko, K; Xu, S, 2012) |
| "Metformin is a well-tolerated biguanide drug used for decades to treat type 2 diabetes mellitus." | 2.82 | Insulin-Like Growth Factor 1/Mammalian Target of Rapamycin and AMP-Activated Protein Kinase Signaling Involved in the Effects of Metformin in the Human Endometrial Cancer. ( Cai, D; Feng, M; Qi, Y; Sun, H; Wu, X; Zhao, X, 2016) |
| "Metformin also plays a direct inhibition of cancer cell growth via the inhibitory effects of AMP-activated protein kinase on the mTOR pathway, which regulates cell growth and proliferation." | 2.48 | Does use of metformin protect against cancer in Type 2 diabetes mellitus? ( Benso, A; Bo, S; Durazzo, M; Ghigo, E, 2012) |
| "Metformin could inhibit the expression of CCNE1, which is associated with the anti-proliferative effect of tumor cells." | 1.91 | CCNE1 is a potential target of Metformin for tumor suppression of ovarian high-grade serous carcinoma. ( Chu, TY; Huang, HS; Liou, YL; Mei, J; Tian, H; Wang, J; Wu, N; Zhang, W, 2023) |
| "Metformin has been reported to affect cancer cells' metabolism and proliferation mainly through the activation of AMP-activated protein kinase (AMPK)." | 1.62 | Metformin Dysregulates the Unfolded Protein Response and the WNT/β-Catenin Pathway in Endometrial Cancer Cells through an AMPK-Independent Mechanism. ( Beguinot, F; Calì, G; Conza, D; Fiory, F; Insabato, L; Mirra, P; Ulianich, L, 2021) |
| "Sixty-five patients diagnosed as endometrial carcinoma were grouped into (n = 33) and non-treatment mixed (n = 32) for analysis." | 1.48 | Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling. ( Cai, D; Feng, M; Sun, H; Wan, Q; Zhao, J; Zhao, X; Zhao, Y, 2018) |
| "Metformin therapy was prescribed in 190 (81%) patients." | 1.46 | Metformin use associated with lower risk of cancer in patients with diabetes mellitus type 2. ( Gušić, E; Kulo Ćesić, A; Kusturica, J; Maleškić, S; Rakanović-Todić, M; Šečić, D, 2017) |
| "Metformin displays both direct and indirect anti-tumor effects." | 1.42 | Metformin reverts the secretion of CXCL8 induced by TNF-α in primary cultures of human thyroid cells: an additional indirect anti-tumor effect of the drug. ( Chiovato, L; Coperchini, F; Magri, F; Pignatti, P; Rotondi, M, 2015) |
| "NUT midline carcinoma is a rare entity arising primarily in the midline of teenagers and young adults." | 1.42 | NUT Midline Carcinoma: Morphoproteomic Characterization with Genomic and Therapeutic Correlates. ( Brown, RE; McGuire, MF; Sun, H; Zhang, S, 2015) |
| "Oral metformin treatment via drinking water significantly delayed tumor growth in both tumor development model and established tumor models." | 1.40 | Therapeutic potential of metformin in papillary thyroid cancer in vitro and in vivo. ( Cho, SW; Han, SK; Kim, YA; Oh, BC; Park, DJ; Park, YJ; Sun, HJ; Yi, KH, 2014) |
| "Metformin has been shown to be useful in reducing insulin resistance by restoring sensitivity." | 1.40 | Cisplatin combined with metformin inhibits migration and invasion of human nasopharyngeal carcinoma cells by regulating E-cadherin and MMP-9. ( Jiang, CC; Jiang, ZW; Li, HH; Liu, H; Sun, XJ; Zhang, P, 2014) |
| "A panel of 15 HNSCC cell lines was assayed for glucose and glutamine dependence and sensitivity to metabolic inhibitors." | 1.37 | Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. ( Davis-Malesevich, M; Fokt, I; Frederick, MJ; Myers, JN; Ow, TJ; Pickering, CR; Priebe, W; Sandulache, VC; Zhou, G, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.13) | 29.6817 |
| 2010's | 27 (84.38) | 24.3611 |
| 2020's | 4 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Zaccari, P | 1 |
| Archibugi, L | 1 |
| Belfiori, G | 1 |
| Nista, E | 1 |
| dell'Anna, G | 1 |
| Crippa, S | 1 |
| Schepis, T | 1 |
| Tacelli, M | 1 |
| Aleotti, F | 1 |
| Petrone, MC | 1 |
| Mariani, A | 1 |
| Costamagna, G | 1 |
| Gasbarrini, A | 1 |
| Larghi, A | 1 |
| Falconi, M | 1 |
| Arcidiacono, PG | 1 |
| Capurso, G | 1 |
| Mei, J | 1 |
| Tian, H | 1 |
| Huang, HS | 1 |
| Wu, N | 1 |
| Liou, YL | 1 |
| Chu, TY | 1 |
| Wang, J | 1 |
| Zhang, W | 1 |
| Nunes, M | 1 |
| Duarte, D | 1 |
| Vale, N | 1 |
| Ricardo, S | 1 |
| Conza, D | 1 |
| Mirra, P | 1 |
| Calì, G | 1 |
| Insabato, L | 1 |
| Fiory, F | 1 |
| Beguinot, F | 1 |
| Ulianich, L | 1 |
| Kusturica, J | 1 |
| Kulo Ćesić, A | 1 |
| Gušić, E | 1 |
| Maleškić, S | 1 |
| Rakanović-Todić, M | 1 |
| Šečić, D | 1 |
| Zhao, Y | 2 |
| Sun, H | 3 |
| Feng, M | 2 |
| Zhao, J | 1 |
| Zhao, X | 2 |
| Wan, Q | 1 |
| Cai, D | 2 |
| Hahn, SS | 1 |
| Tang, Q | 1 |
| Zheng, F | 1 |
| Zhao, S | 1 |
| Wu, J | 1 |
| Chen, J | 1 |
| Shao, R | 1 |
| Li, X | 1 |
| Feng, Y | 1 |
| Lin, JF | 1 |
| Billig, H | 1 |
| Cho, SW | 1 |
| Yi, KH | 1 |
| Han, SK | 1 |
| Sun, HJ | 1 |
| Kim, YA | 1 |
| Oh, BC | 1 |
| Park, YJ | 1 |
| Park, DJ | 1 |
| Sun, XJ | 1 |
| Zhang, P | 1 |
| Li, HH | 1 |
| Jiang, ZW | 1 |
| Jiang, CC | 1 |
| Liu, H | 1 |
| Li, H | 1 |
| Chen, X | 1 |
| Yu, Y | 1 |
| Wang, Z | 1 |
| Zuo, Y | 1 |
| Li, S | 1 |
| Yang, D | 1 |
| Hu, S | 1 |
| Xiang, M | 1 |
| Xu, Z | 1 |
| Yu, Z | 1 |
| Rotondi, M | 1 |
| Coperchini, F | 1 |
| Pignatti, P | 1 |
| Magri, F | 1 |
| Chiovato, L | 1 |
| Zhang, Y | 2 |
| Li, MX | 1 |
| Wang, H | 1 |
| Zeng, Z | 1 |
| Li, XM | 1 |
| Sakoda, LC | 1 |
| Ferrara, A | 1 |
| Achacoso, NS | 1 |
| Peng, T | 1 |
| Ehrlich, SF | 1 |
| Quesenberry, CP | 1 |
| Habel, LA | 1 |
| Chen, G | 2 |
| Nicula, D | 1 |
| Renko, K | 2 |
| Derwahl, M | 2 |
| Mutoh, M | 1 |
| Ishikawa, H | 1 |
| Giannoni, E | 1 |
| Taddei, ML | 1 |
| Morandi, A | 1 |
| Comito, G | 1 |
| Calvani, M | 1 |
| Bianchini, F | 1 |
| Richichi, B | 1 |
| Raugei, G | 1 |
| Wong, N | 1 |
| Tang, D | 1 |
| Chiarugi, P | 1 |
| McGuire, MF | 1 |
| Zhang, S | 1 |
| Brown, RE | 1 |
| Laskov, I | 1 |
| Abou-Nader, P | 1 |
| Amin, O | 1 |
| Philip, CA | 1 |
| Beauchamp, MC | 1 |
| Yasmeen, A | 1 |
| Gotlieb, WH | 1 |
| Qi, Y | 1 |
| Wu, X | 1 |
| Zakikhani, M | 3 |
| Dowling, RJ | 1 |
| Sonenberg, N | 1 |
| Pollak, MN | 1 |
| Algire, C | 1 |
| Amrein, L | 1 |
| Panasci, L | 1 |
| Pollak, M | 2 |
| Engelman, JA | 1 |
| Cantley, LC | 1 |
| Memmott, RM | 1 |
| Mercado, JR | 1 |
| Maier, CR | 1 |
| Kawabata, S | 1 |
| Fox, SD | 1 |
| Dennis, PA | 1 |
| Xie, Y | 1 |
| Wang, YL | 1 |
| Yu, L | 1 |
| Hu, Q | 1 |
| Ji, L | 1 |
| Liao, QP | 1 |
| Sandulache, VC | 1 |
| Ow, TJ | 1 |
| Pickering, CR | 1 |
| Frederick, MJ | 1 |
| Zhou, G | 1 |
| Fokt, I | 1 |
| Davis-Malesevich, M | 1 |
| Priebe, W | 1 |
| Myers, JN | 1 |
| Zhao, L | 1 |
| Wen, ZH | 1 |
| Jia, CH | 1 |
| Li, M | 1 |
| Luo, SQ | 1 |
| Bai, XC | 1 |
| Bayraktar, S | 1 |
| Hernadez-Aya, LF | 1 |
| Lei, X | 1 |
| Meric-Bernstam, F | 1 |
| Litton, JK | 1 |
| Hsu, L | 1 |
| Hortobagyi, GN | 1 |
| Gonzalez-Angulo, AM | 1 |
| Dool, CJ | 1 |
| Mashhedi, H | 1 |
| David, S | 1 |
| Birman, E | 1 |
| Carboni, JM | 1 |
| Gottardis, M | 1 |
| Blouin, MJ | 1 |
| Xu, S | 1 |
| Bo, S | 1 |
| Benso, A | 1 |
| Durazzo, M | 1 |
| Ghigo, E | 1 |
| Campagnoli, C | 1 |
| Pasanisi, P | 1 |
| Abbà, C | 1 |
| Ambroggio, S | 1 |
| Biglia, N | 1 |
| Brucato, T | 1 |
| Colombero, R | 1 |
| Danese, S | 1 |
| Donadio, M | 1 |
| Venturelli, E | 1 |
| Zito, G | 1 |
| Berrino, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules Size in Type 2 Diabetes: a 2-years Prospective Multicentric Study[NCT04298684] | Phase 4 | 90 participants (Anticipated) | Interventional | 2021-01-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for metformin and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma; Endometrial Neoplasms; Endometrium; Female; Humans; Metfo | 2014 |
Does use of metformin protect against cancer in Type 2 diabetes mellitus?
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Diabetes Mellitus, Typ | 2012 |
2 trials available for metformin and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Insulin-Like Growth Factor 1/Mammalian Target of Rapamycin and AMP-Activated Protein Kinase Signaling Involved in the Effects of Metformin in the Human Endometrial Cancer.
Topics: Adult; Aged; AMP-Activated Protein Kinases; Carcinoma; Endometrial Neoplasms; Endometrium; Female; H | 2016 |
Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study.
Topics: Adult; Aged; Algorithms; Breast Neoplasms; Carcinoma; Diabetes Mellitus; Dose-Response Relationship, | 2012 |
28 other studies available for metformin and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Risk factors for the occurrence of ampullary tumors: A case-control study.
Topics: Adenoma; Ampulla of Vater; Aspirin; Carcinoma; Case-Control Studies; Common Bile Duct Neoplasms; Duo | 2022 |
CCNE1 is a potential target of Metformin for tumor suppression of ovarian high-grade serous carcinoma.
Topics: Animals; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cyclin E; Diabetes Mellitus, Type 2; Femal | 2023 |
The Antineoplastic Effect of Carboplatin Is Potentiated by Combination with Pitavastatin or Metformin in a Chemoresistant High-Grade Serous Carcinoma Cell Line.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cell | 2022 |
Metformin Dysregulates the Unfolded Protein Response and the WNT/β-Catenin Pathway in Endometrial Cancer Cells through an AMPK-Independent Mechanism.
Topics: AMP-Activated Protein Kinase Kinases; Carcinoma; Cell Line, Tumor; Endometrial Neoplasms; Endoplasmi | 2021 |
Metformin use associated with lower risk of cancer in patients with diabetes mellitus type 2.
Topics: Adult; Aged; Carcinoma; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglyc | 2017 |
Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling.
Topics: Carcinoma; Cell Proliferation; Endometrial Neoplasms; Endometrium; Female; Humans; Metformin; Middle | 2018 |
Repression of integrin-linked kinase by antidiabetes drugs through cross-talk of PPARγ- and AMPKα-dependent signaling: role of AP-2α and Sp1.
Topics: AMP-Activated Protein Kinases; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene | 2014 |
Therapeutic potential of metformin in papillary thyroid cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma; Carcinoma, Papillary; Cells | 2014 |
Cisplatin combined with metformin inhibits migration and invasion of human nasopharyngeal carcinoma cells by regulating E-cadherin and MMP-9.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cadherins; Carcinoma; Cell Li | 2014 |
Metformin inhibits the growth of nasopharyngeal carcinoma cells and sensitizes the cells to radiation via inhibition of the DNA damage repair pathway.
Topics: Apoptosis; Carcinoma; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA | 2014 |
Metformin reverts the secretion of CXCL8 induced by TNF-α in primary cultures of human thyroid cells: an additional indirect anti-tumor effect of the drug.
Topics: Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Cell Death; Cell Proliferation; Cells, Cultu | 2015 |
Metformin down-regulates endometrial carcinoma cell secretion of IGF-1 and expression of IGF-1R.
Topics: Carcinoma; Cell Line, Tumor; Down-Regulation; Endometrial Neoplasms; Female; Humans; Insulin-Like Gr | 2015 |
Metformin use and lung cancer risk in patients with diabetes.
Topics: Adult; Aged; Carcinoma; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agen | 2015 |
Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Cycle Checkpoints; Cell Line, Tumor; Dose-Response | 2015 |
Metformin Use and Lung Cancer Risk--Letter.
Topics: Carcinoma; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lung Neoplasms; Male; Met | 2015 |
Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs oxphos and prostate cancer metastatic spread.
Topics: Active Transport, Cell Nucleus; Animals; Binding Sites; Carcinoma; Carrier Proteins; Cell Line, Tumo | 2015 |
NUT Midline Carcinoma: Morphoproteomic Characterization with Genomic and Therapeutic Correlates.
Topics: Adolescent; Adult; Carcinoma; Enhancer of Zeste Homolog 2 Protein; Female; Humans; Immunohistochemis | 2015 |
Metformin Increases E-cadherin in Tumors of Diabetic Patients With Endometrial Cancer and Suppresses Epithelial-Mesenchymal Transition in Endometrial Cancer Cell Lines.
Topics: Adult; Aged; Aged, 80 and over; Cadherins; Carcinoma; Cell Line, Tumor; Cell Movement; Diabetes Mell | 2016 |
The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase.
Topics: Adiponectin; AMP-Activated Protein Kinases; Carcinoma; Cell Proliferation; Colonic Neoplasms; Cytost | 2008 |
Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; Apoptosis; Carcinoma; Colonic Neopla | 2010 |
Chemoprevention meets glucose control.
Topics: Animals; Blood Glucose; Carcinoma; Chemoprevention; Humans; Hypoglycemic Agents; Lung Neoplasms; Med | 2010 |
Metformin prevents tobacco carcinogen--induced lung tumorigenesis.
Topics: Adenylate Kinase; Administration, Oral; Animals; Antineoplastic Agents; Carcinogens; Carcinoma; Drug | 2010 |
Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Lin | 2011 |
Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells.
Topics: Adenosine Triphosphate; Carcinoma; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Prol | 2011 |
Metformin induces G1 cell cycle arrest and inhibits cell proliferation in nasopharyngeal carcinoma cells.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Antineoplastic Agents; Carcinom | 2011 |
Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Carcinoma; Case-Control Studies; Diabetes Mellitus | 2012 |
IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer.
Topics: Alloxan; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell | 2011 |
Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents.
Topics: Adenocarcinoma, Follicular; Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Cell Cycle; Cell D | 2012 |